Article Text

Download PDFPDF
Low-grade serous ovarian carcinoma: an evolution toward targeted therapy
  1. Ioannis A Voutsadakis
  1. Section of Internal Medicine Division of Clinical Sciences, Northern Ontario School of Medicine, Sudbury, ON, Canada
  1. Correspondence to Dr Ioannis A Voutsadakis, Sault Area Hospital, Sault Sainte Marie, ON P6B 0A8, Canada; ivoutsadakis{at}


Low-grade serous ovarian carcinoma and its high-grade serous ovarian carcinoma counterpart differ in their precursor lesions, molecular profile, natural history, and response to therapies. As such, low-grade serous ovarian carcinoma needs to be studied separately from high-grade serous ovarian carcinoma, despite challenges stemming from its rarity. A deeper understanding of the pathogenesis of low-grade serous ovarian carcinoma and the most common molecular defects and pathways involved in the carcinogenesis of the ovarian epithelium from normal to serous borderline ovarian tumors to low-grade serous ovarian carcinoma will help develop better therapies. By adopting targeted approaches there may be an opportunity to integrate novel therapies without the need for robust numbers in clinical trials. This manuscript will discuss low-grade serous ovarian carcinoma and focus on the arising treatments being developed with an improved understanding of the pathogenesis of this disease.

  • low-grade serous ovarian carcinoma
  • micro-papillary ovarian cancer
  • genomics
  • BRAF
  • KRAS
  • targeted therapeutics

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors IAV is the sole contributor to this article.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial, or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.